ClinicalTrials.gg
CompletedNCT01499446Updated Sep 15, 2016

A Study of GW685698X 100mcg Administered Once Daily Either in the Morning or the Evening and GW685698X 250mcg Administered Once Daily in the Evening Via DISKHALER for 28 Days in Subjects With Persistent Bronchial Asthma.

A Phase 2 interventional study of GW685698X (fluticasone furoate) 100mcg Morning and GW685698X (fluticasone furoate) 100mcg Evening in Asthma, sponsored by GlaxoSmithKline. Completed at 64 sites in 13 countries. Open to participants aged 16 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-09-15.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
669
Allocation
Randomized
Ages
16 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing fluticasone furoate in Asthma — none open to participants now, 3 under way, 2 of them phase 3. fluticasone furoate · Asthma.

Enrollment
4th of 40
669 · median 102
Started
2003
the only one that year
Phase 2
12 of 40
none open now
Registered
22nd of 40
by date
Lead sponsor
36 of 40
GlaxoSmithKline

Among the 40 studies testing fluticasone furoate in Asthma, this one is the 4th largest by enrollment, is the only one that started in 2003, is one of 12 in phase 2, and was the 22nd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing fluticasone furoate in Asthma is open now. The open studies under Asthma, anywhere →

About fluticasone furoate

fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 16 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing fluticasone furoate in Asthma as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of GW685698X 100mcg once daily either in the morning or the evening and GW685698X 250mcg administered once daily in the evening via DISKHALER for 28 days in subjects with persistent bronchial asthma.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
16 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Outpatients aged between 16- 65 years.
  • Male and female; female subjects must be non-child bearing potential or of childbearing potenetial with negative pregnancy test and willing to use acceptable methods
  • Documented clinical history of persistent asthma first diagnosed at least 6 months prior to Visit 1
  • Currently receiving inhaled short-acting beta-2 agonists for symptom relief
  • A lung function of between 50 to 90% predicted (PEF)
  • Increase in PEF of at least15%, 20 minutes after inhalation of 400mcg salbutamol

Exclusion criteria

Exclusion Criteria:

  • History of respiratory tract infection and/or exacerbation of asthma within a period of 4 weeks prior to Visit 1
  • History of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnoea, respiratory arrest or hypoxia seizures.
  • A history of two or more asthma exacerbations requiring treatment with oral or hospitalisation in the 6 months before Visit 1.
  • Past or present disease that, as judged by the investigator, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, , hepatic disease, renal disease, haematologic disease, neurological disease, endocrine disease or pulmonary disease (including, but not confined to, chronic bronchitis, emphysema, bronchiectasis with the need of treatment, cystic fibrosis and bronchopulmonary dysplasia).
  • Known or suspected sensitivity to corticosteroids, VENTOLIN, or the constituents of ROTADISKS (e.g., lactose).
  • Undergoing allergen desensitisation therapy.
  • Neurological or psychiatric disease or history of drug or alcohol abuse that would interfere with the subject's proper completion of the protocol requirements.
  • Is a current smoker or has a smoking history of 10 pack years or more (e.g., 20 cigarettes/day for 10 years). Note: Current smoker is defined as currently smoking or stopped smoking within 6 months of screening visit.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
669 participants (actual)

Study arms

  • Experimental
    GW685698X (fluticasone furoate) 100mcg Morning

    Drug: GW685698X (fluticasone furoate) 100mcg Morning

  • Experimental
    GW685698X (fluticasone furoate) 100mcg Evening

    Drug: GW685698X (fluticasone furoate) 100mcg Evening

  • Experimental
    GW685698X (fluticasone furoate) 250mcg Evening

    Drug: GW685698X (fluticasone furoate) 250mcg Evening

  • Placebo comparator
    Placebo

    Drug: GW685698X (fluticasone furoate) 100mcg Morning · Drug: GW685698X (fluticasone furoate) 100mcg Evening · Drug: GW685698X (fluticasone furoate) 250mcg Evening · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Peak expiratory flow (PEF)

    Mean change from baseline in daily trough (pre study treatment and pre bronchodilator) PEF during the 28 day treatment period with GW685698X 100mcg once daily in the morning compared with GW685698X 100mcg once daily in the evening by inhalation via DISKHALER.

    Time frame: 28 days

Secondary outcomes

  1. Peak expiratory flow (PEF)

    Mean change from baseline in daily trough (pre study treatment and pre bronchodilator) PEF during the 28 day treatment period with GW685698X 250mcg once daily compared with GW685698X 100mcg once daily both administered in the evening by inhalation via DISKHALER.

    Time frame: 28 days

  2. PEF

    Mean change from baseline in daily trough (pre study treatment and pre bronchodilator) PEF during the 28 day treatment period with GW685698X 100mcg once daily in the morning, 100mcg once daily in the evening, or GW685698X 250mcg once daily in the evening, compared with placebo

    Time frame: 28 days

  3. Clinic lung function

    Change from baseline in pre bronchodilator clinic lung function (forced expiratory volume in 1 second \[FEV1\] and PEF) after 28 days of treatment with GW685698X 250mcg once daily in the evening compared with GW685698X 100mcg once daily in the evening

    Time frame: 28 days

07

Study locations

64 sites
  • GSK Investigational Site
    Porto Alegre, Rio Grande Do Sul 40110-160, Brazil
  • GSK Investigational Site
    Pleven, 5800, Bulgaria
  • GSK Investigational Site
    Sofia, 1431/1000, Bulgaria
  • GSK Investigational Site
    Sofia, 1606, Bulgaria
  • GSK Investigational Site
    Sofia, 1619, Bulgaria
  • GSK Investigational Site
    Varna, 9010, Bulgaria
  • GSK Investigational Site
    Santiago, Región Metro De Santiago 7500551, Chile
  • GSK Investigational Site
    Santiago, Región Metro De Santiago 7500691, Chile
  • GSK Investigational Site
    Osijek, 31000, Croatia
  • GSK Investigational Site
    Split, 21000, Croatia
  • GSK Investigational Site
    Zagreb, 10000, Croatia
  • GSK Investigational Site
    Kohtal-Jdrve, 31 025, Estonia
  • GSK Investigational Site
    Parnu, 80024, Estonia
  • GSK Investigational Site
    Tallinn, 1162, Estonia
  • GSK Investigational Site
    Tartu, 51014, Estonia
  • GSK Investigational Site
    Schwetzingen, Baden-Wuerttemberg 68723, Germany
  • GSK Investigational Site
    Weinheim, Baden-Wuerttemberg 69469, Germany
  • GSK Investigational Site
    Eschwege, Hessen 37269, Germany
  • GSK Investigational Site
    Gelnhausen, Hessen 63571, Germany
  • GSK Investigational Site
    Kassel, Hessen 34117, Germany
  • GSK Investigational Site
    Hannover, Niedersachsen 30159, Germany
  • GSK Investigational Site
    Hannover, Niedersachsen 30167, Germany
  • GSK Investigational Site
    Lueneburg, Niedersachsen 21335, Germany
  • GSK Investigational Site
    Guetersloh, Nordrhein-Westfalen 33330, Germany
  • GSK Investigational Site
    Annaberg, Sachsen 09456, Germany
  • GSK Investigational Site
    Aue, Sachsen 08280, Germany
  • GSK Investigational Site
    Geesthacht, Schleswig-Holstein 21502, Germany
  • GSK Investigational Site
    Erfurt, Thueringen 99084, Germany
  • GSK Investigational Site
    Berlin, 10365, Germany
  • GSK Investigational Site
    Berlin, 10585, Germany
  • GSK Investigational Site
    Berlin, 10717, Germany
  • GSK Investigational Site
    Berlin, 10969, Germany
  • GSK Investigational Site
    Berlin, 13086, Germany
  • GSK Investigational Site
    Berlin, 13597, Germany
  • GSK Investigational Site
    Athens, 115 28, Greece
  • GSK Investigational Site
    Athens, 15669, Greece
  • GSK Investigational Site
    Papagos/Athens, 15669, Greece
  • GSK Investigational Site
    Törökbálint, 2045, Hungary
  • GSK Investigational Site
    Eboli (SA), Campania 84025, Italy
  • GSK Investigational Site
    Napoli, Campania 80131, Italy
  • GSK Investigational Site
    Salerno, Campania 84126, Italy
  • GSK Investigational Site
    Ferrara, Emilia-Romagna 44100, Italy
  • GSK Investigational Site
    Genova, Liguria 16132, Italy
  • GSK Investigational Site
    Sesto San Giovanni (MI), Lombardia 20099, Italy
  • GSK Investigational Site
    Torrette (AN), Marche 60126, Italy
  • GSK Investigational Site
    Firenze, Toscana 50134, Italy
  • GSK Investigational Site
    Pisa, Toscana 56124, Italy
  • GSK Investigational Site
    Bussolengo (VR), Veneto 37012, Italy
  • GSK Investigational Site
    Padova, Veneto 35128, Italy
  • GSK Investigational Site
    Mexico, D.F., 06720, Mexico
  • GSK Investigational Site
    Mexico, 04530, Mexico
  • GSK Investigational Site
    Brasov, Romania
  • GSK Investigational Site
    Bucharest, 050159, Romania
  • GSK Investigational Site
    Bucuresti, 70000, Romania
  • GSK Investigational Site
    Kazan, 420015, Russian Federation
  • GSK Investigational Site
    Moscow, 115446, Russian Federation
  • GSK Investigational Site
    Moscow, 115478, Russian Federation
  • GSK Investigational Site
    Moscow, 123 182, Russian Federation
  • GSK Investigational Site
    St. Petersburg, 197 089, Russian Federation
  • GSK Investigational Site
    St. Petersburg, 197022, Russian Federation
  • GSK Investigational Site
    Tomsk, 634 050, Russian Federation
  • GSK Investigational Site
    Volgograd, 400130, Russian Federation
  • GSK Investigational Site
    Bloemfontein, 9300, South Africa
  • GSK Investigational Site
    Cape Town, 7500, South Africa
08

References and documents

Publications

  • O'Byrne PM, Jacques L, Goldfrad C, Kwon N, Perrio M, Yates LJ, Busse WW. Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma. Respir Res. 2016 Nov 24;17(1):157. doi: 10.1186/s12931-016-0473-x. PubMed 27881132 ↗
  • Medley H, Orozco S, Allen A. Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma. Clin Ther. 2012 Aug;34(8):1683-95. doi: 10.1016/j.clinthera.2012.06.024. Epub 2012 Jul 13. PubMed 22796247 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2003, a primary completion of Mar 2004 and a completion of Mar 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2011
First posted
Dec 26, 2011
Start
Sep 2003
Primary completionActual
Mar 2004
CompletionActual
Mar 2004
Last update
Sep 15, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01499446
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Dec 26, 2011
Start date
Sep 2003
Primary completion
Mar 2004
Completion
Mar 2004
Last update
Sep 15, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone furoate

Start the discussion